Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Firefly Neuroscience, Inc. (AIFF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AIFF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.36% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.84M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 |
52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4802.33% |
Management Effectiveness
Return on Assets (TTM) -86.34% | Return on Equity (TTM) -860.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37724522 | Price to Sales(TTM) 279.43 |
Enterprise Value 37724522 | Price to Sales(TTM) 279.43 | ||
Enterprise Value to Revenue 271.4 | Enterprise Value to EBITDA - | Shares Outstanding 12861100 | Shares Floating 8202680 |
Shares Outstanding 12861100 | Shares Floating 8202680 | ||
Percent Insiders 40.48 | Percent Institutions 9.56 |
Upturn AI SWOT
Firefly Neuroscience, Inc.
Company Overview
History and Background
Firefly Neuroscience, Inc. is a neurotechnology company focused on advancing brain health assessment through EEG-based solutions. Founded in 2015, the company has developed technology aimed at providing objective, quantitative insights into brain function to aid in the diagnosis and treatment of neurological and psychiatric disorders.
Core Business Areas
- Clinical EEG Analysis: Provides EEG-based solutions for clinicians to aid in diagnosing neurological and psychiatric conditions.
- Pharmaceutical Research: Partners with pharmaceutical companies to utilize EEG data in clinical trials for drug development and personalized medicine.
- Digital Health: Developing digital health solutions to assess and monitor brain health through EEG data.
Leadership and Structure
The leadership team consists of experienced executives in the medical device and pharmaceutical industries. The organizational structure is designed to facilitate innovation and commercialization of its EEG technology.
Top Products and Market Share
Key Offerings
- Firefly Brain Network Analysis (BNA): Proprietary EEG analysis platform providing objective metrics of brain function. The market share is still developing. Competitors include companies offering quantitative EEG analysis, such as NeuroGuide and BrainScope.
Market Dynamics
Industry Overview
The neurotechnology market is growing, driven by increasing awareness of brain health and advancements in EEG technology. There's growing demand for objective measures of brain function in the diagnosis and treatment of neurological and psychiatric disorders.
Positioning
Firefly Neuroscience positions itself as a leader in quantitative EEG analysis, with its BNA platform providing advanced insights into brain function. The company aims to improve diagnostic accuracy and treatment outcomes in neurological and psychiatric care.
Total Addressable Market (TAM)
The estimated total addressable market for brain health and diagnostics is in the billions of dollars. Firefly Neuroscience is positioned to capture a significant portion of this market by offering innovative EEG-based solutions.
Upturn SWOT Analysis
Strengths
- Proprietary EEG analysis platform
- Experienced leadership team
- Partnerships with pharmaceutical companies
- Focus on objective brain function measurement
Weaknesses
- Limited market penetration
- Requires regulatory approvals for some applications
- Dependent on research and development
- Small company size in comparison to competitors
Opportunities
- Expanding partnerships with healthcare providers
- Development of new EEG-based applications
- Increasing adoption of digital health solutions
- Growing demand for objective brain function assessment
Threats
- Competition from established neurotechnology companies
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- ANTM
- EBSO
Competitive Landscape
Firefly Neuroscience differentiates itself through its proprietary EEG analysis platform and focus on objective brain function measurement. Its smaller size and limited market penetration are disadvantages compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to determine without financials. The company is focused on growth.
Future Projections: Future projections are unavailable, depends on securing contracts.
Recent Initiatives: Recent initiatives include expanding partnerships with healthcare providers and pharmaceutical companies, as well as developing new EEG-based applications.
Summary
Firefly Neuroscience is an early-stage neurotechnology company with a promising EEG analysis platform. Securing strategic partnerships and increasing market penetration will be crucial for its success. It needs to closely monitor competition and adapt to changing market dynamics to capitalize on opportunities in the growing brain health market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Firefly Neuroscience, Inc.
Exchange NASDAQ | Headquaters Kenmore, NY, United States | ||
IPO Launch date 2011-02-23 | CEO & Director Mr. Greg Lipschitz | ||
Sector Technology | Industry Software - Application | Full time employees 13 | Website https://fireflyneuro.com |
Full time employees 13 | Website https://fireflyneuro.com | ||
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.